![PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast artwork](https://is5-ssl.mzstatic.com/image/thumb/Podcasts113/v4/ae/85/a4/ae85a473-ed8f-49c9-b109-e88019bd4bf8/mza_466067069700462642.jpg/100x100bb.jpg)
Richard S. Finn, MD - Patient Stories From the HCC CaseBook: Expert Guidance on Optimizing Outcomes and Care With Newly Available and Emerging Therapies
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
English - August 14, 2020 23:00 - 1 hour - ★★★★ - 8 ratingsScience cme medical education cme credits peerview insession inreview oncology hematology cne Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Go online to PeerView.com/VBH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Liver cancer experts discuss recent developments in the treatment of patients with hepatocellular carcinoma (HCC). Don’t miss this opportunity to learn more about new and emerging treatment strategies and get practical guidance on important clinical treatment decisions, including best practices for therapy sequencing across the disease spectrum and the importance of multidisciplinary care, patient selection, clinical trial enrollment, and adverse event management. Upon completion of this activity, participants should be better able to: Describe the clinical evidence on available multikinase inhibitors and anti-angiogenic agents as first- and second-line treatment options for advanced HCC, Evaluate the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and in combination with targeted therapy, in the advanced HCC disease setting, Review ongoing clinical trials investigating innovative strategies, including combinations of local modalities, such as TACE and TARE, with systemic therapies, such as targeted agents and checkpoint inhibitors, across the HCC disease spectrum, Select safe and effective treatments for patients with advanced HCC across multiple lines of therapy based on clinical evidence, practice guidelines, treatment history, disease factors, AFP levels, and patients’ needs.